54 related articles for article (PubMed ID: 33129194)
1. Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours.
Ariyarathna H; Thomson NA; Aberdein D; Perrott MR; Munday JS
Vet Immunol Immunopathol; 2020 Dec; 230():110142. PubMed ID: 33129194
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer.
Salvi S; Fontana V; Boccardo S; Merlo DF; Margallo E; Laurent S; Morabito A; Rijavec E; Dal Bello MG; Mora M; Ratto GB; Grossi F; Truini M; Pistillo MP
Cancer Immunol Immunother; 2012 Sep; 61(9):1463-72. PubMed ID: 22318401
[TBL] [Abstract][Full Text] [Related]
3. Programmed Death 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Gene Expression in Peripheral Blood Mononuclear Cells Can Serve as Prognostic Biomarkers for Hepatocellular Carcinoma.
Lee JA; Choi HG; Eun HS; Bu J; Jang TM; Lee J; Son CY; Kim MS; Rou WS; Kim SH; Lee BS; Kim HN; Lee TH; Jeon HJ
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672574
[TBL] [Abstract][Full Text] [Related]
4. Collagen modifications predictive of lymph node metastasis in dogs with carcinoma in mixed tumours.
Garcia APV; Taborda DYO; Reis LA; de Paula AM; Cassali GD
Front Vet Sci; 2024; 11():1362693. PubMed ID: 38511192
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates in veterinary medicine: The new horizon for use.
Suva LJ; Cooper A; Watts AE; Ebetino FH; Price J; Gaddy D
Bone; 2021 Jan; 142():115711. PubMed ID: 33141069
[TBL] [Abstract][Full Text] [Related]
6. Are B-symptoms more reliable prognostic indicators than substage in canine nodal diffuse large B-cell lymphoma.
Škor O; Bicanová L; Wolfesberger B; Fuchs-Baumgartinger A; Ruetgen B; Štěrbová M; Schwendenwein I; Kleiter M
Vet Comp Oncol; 2021 Mar; 19(1):201-208. PubMed ID: 33136315
[TBL] [Abstract][Full Text] [Related]
7. Characterization of WWOX expression and function in canine mast cell tumors and malignant mast cell lines.
Makii R; Cook H; Louke D; Breitbach J; Jennings R; Premanandan C; Green EM; Fenger JM
BMC Vet Res; 2020 Oct; 16(1):415. PubMed ID: 33129329
[TBL] [Abstract][Full Text] [Related]
8. Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate.
Cascio MJ; Whitley EM; Sahay B; Cortes-Hinojosa G; Chang LJ; Cowart J; Salute M; Sayour E; Dark M; Sandoval Z; Mitchell DA; Milner RJ
Vet Immunol Immunopathol; 2021 Feb; 232():110169. PubMed ID: 33387703
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma.
Maekawa N; Konnai S; Nishimura M; Kagawa Y; Takagi S; Hosoya K; Ohta H; Kim S; Okagawa T; Izumi Y; Deguchi T; Kato Y; Yamamoto S; Yamamoto K; Toda M; Nakajima C; Suzuki Y; Murata S; Ohashi K
NPJ Precis Oncol; 2021 Feb; 5(1):10. PubMed ID: 33580183
[TBL] [Abstract][Full Text] [Related]
10. Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs.
Pantelyushin S; Ranninger E; Guerrera D; Hutter G; Maake C; Markkanen E; Bettschart-Wolfensberger R; Rohrer Bley C; Läubli H; Vom Berg J
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33668625
[TBL] [Abstract][Full Text] [Related]
11. Characterizing the molecular and immune landscape of canine bladder cancer.
Cronise KE; Das S; Hernandez BG; Regan DP; Dailey DD; McGeachan RI; Lana SE; Page RL; Gustafson DL; Duval DL
Vet Comp Oncol; 2022 Mar; 20(1):69-81. PubMed ID: 34021685
[TBL] [Abstract][Full Text] [Related]
12. Programmed Death-Ligand (PD-L1), Epidermal Growth Factor (EGF), Relaxin, and Matrix Metalloproteinase-3 (MMP3): Potential Biomarkers of Malignancy in Canine Mammary Neoplasia.
Galadima M; Teles M; Pastor J; Hernández-Losa J; Rodríguez-Gil JE; Rivera Del Alamo MM
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256245
[TBL] [Abstract][Full Text] [Related]
13. CTLA-4 and its inhibitors in esophageal cancer: efficacy of therapy and potential mechanisms of adverse events.
Tian C; Wang X; Zhang S
Am J Cancer Res; 2023; 13(7):3140-3156. PubMed ID: 37559996
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry
Sirivisoot S; Boonkrai C; Wongtangprasert T; Phakham T; Muanwein P; Pisitkun T; Sawangmake C; Radtanakatikanon A; Rungsipipat A
Vet Q; 2023 Dec; 43(1):1-9. PubMed ID: 37477617
[TBL] [Abstract][Full Text] [Related]
15. Clinical Implications of Immune Checkpoints and the RANK/RANK-L Signaling Pathway in High-Grade Canine Mast Cell Tumors.
Talavera Guillén NC; Barboza de Nardi A; Noleto de Paiva F; Dias QC; Pinheiro Fantinatti A; Fávaro WJ
Animals (Basel); 2023 Jun; 13(12):. PubMed ID: 37370399
[TBL] [Abstract][Full Text] [Related]
16. Synthetic biology-inspired cell engineering in diagnosis, treatment, and drug development.
Zhao N; Song Y; Xie X; Zhu Z; Duan C; Nong C; Wang H; Bao R
Signal Transduct Target Ther; 2023 Mar; 8(1):112. PubMed ID: 36906608
[TBL] [Abstract][Full Text] [Related]
17. Development of Monoclonal Antibodies Targeting Canine PD-L1 and PD-1 and Their Clinical Relevance in Canine Apocrine Gland Anal Sac Adenocarcinoma.
Minoli L; Licenziato L; Kocikowski M; Cino M; Dziubek K; Iussich S; Fanelli A; Morello E; Martano M; Hupp T; Vojtesek B; Parys M; Aresu L
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551672
[TBL] [Abstract][Full Text] [Related]
18. Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy.
Maekawa N; Konnai S; Asano Y; Sajiki Y; Deguchi T; Okagawa T; Watari K; Takeuchi H; Takagi S; Hosoya K; Kim S; Ohta H; Kato Y; Suzuki Y; Murata S; Ohashi K
Sci Rep; 2022 Jun; 12(1):9265. PubMed ID: 35665759
[TBL] [Abstract][Full Text] [Related]
19. Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer.
Von Rueden SK; Fan TM
Front Oncol; 2021; 11():773420. PubMed ID: 34869014
[TBL] [Abstract][Full Text] [Related]
20. A Comparative View on Molecular Alterations and Potential Therapeutic Strategies for Canine Oral Melanoma.
Hardwick L
Vet Sci; 2021 Nov; 8(11):. PubMed ID: 34822659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
